FDA panel rejects Pfizer's arthritis drug as too risky
A panel of U.S. health advisers says an experimental arthritis drug is too risky, even with limits on its use
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.U.S. health advisers sharply criticized an experimental arthritis drug Thursday, saying that it was too risky, even with limits on its use.
The expert panel for the Food and Drug Administration voted 19-1 that the drug's modest benefits don’t outweigh its considerable risks, even with proposed measures to restrict who gets the medicine. Pfizer is seeking FDA approval of the drug, called tanezumab, to treat pain from mild to moderate arthritis in the hips and knees. It is given by injection every two months.
In studies, a small percentage of participants saw their joint damage get worse faster, sometimes requiring hip or knee replacements. Others had swelling or nerve damage. In some, healthy joints were damaged.
“I’m concerned about the long-term side effects,” said Dr. Lee D. Katz, a radiology expert at Yale University School of Medicine, citing the physician’s oath to “first do no harm.”
The FDA is not required to follow recommendations or advice from its outside experts, but usually does. A detailed review of the drug by FDA staff members reached the same conclusions as the panel.
In a statement, Pfizer said it was disappointed in the vote on the drug, which has been in development for 15 years.
“We will continue to work with the FDA to determine next steps,” said Jim Rusnak, chief development officer for internal medicine.
During a hearing that spanned two days, many of the experts noted tanezumab didn’t work better than nonsteroidal anti-inflammatory drugs commonly used for arthritis pain, such as Aleve and Celebrex. They also raised concerns that while people would likely be taking the drug for many years, study participants were only followed for about a year in the longest study.
___
Follow Linda A. Johnson at https://twitter.com/LindaJ_onPharma
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.